Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study

Breast Cancer Research and Treatment

Volumn 124, Issue 1, 2010, Pages 153-161

  Coleman, Robert E ^g   Banks, Linda M ^a   Girgis, Samia I ^a   Vrdoljak, Eduard ^b   Fox, John ^c   Cawthorn, Simon J ^d   Patel, Ashraf ^e   Bliss, Judith M ^f   Coombes, R Charles ^a   Kilburn, Lucy S ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d FRENCHAY HOSPITAL   (United Kingdom)

^e St Margaret's Hospital   (United Kingdom)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g NONE

Author keywords

Adjuvant therapy; Aromatase inhibitor; Bone biomarkers; Bone loss; Bone mineral density; Breast cancer; Exemestane

Indexed keywords

ALKALINE PHOSPHATASE; EXEMESTANE; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN N PROTEINASE; TAMOXIFEN; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT WITHDRAWAL;

ABSORPTIOMETRY, PHOTON; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; AUSTRALIA; BIOLOGICAL MARKERS; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; EUROPE; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS; UNITED STATES;

EID: 77957708501     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1121-7     Document Type: Article

References (15)

1. ATAC Trialists' Group 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(04)17666-6
2. The Breast International (BIG) I-98 Collaborative Group 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258
3. RC Coombes E Hall L Gibson R Paridaens J Jassem T Delozier, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 1:CAS:528:DC%2BD2cXitV2qtbc%3D 10.1056/NEJMoa040331 15014181
4. R Jakesz W Jonat M Gnant M Mittlboeck R Greil C Tausch, et al. 2005 Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462 1:CAS:528:DC%2BD2MXntVeisLw%3D 10.1016/S0140-6736(05)67059-6 16084253
5. OS Din D Dodwell RJ Wakefield RE Coleman 2010 Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120 525 538 1:CAS:528:DC%2BC3cXjs1ajuro%3D 10.1007/s10549-010-0757-7 20157776
6. RE Coleman JJ Body JR Gralow A Lipton 2008 Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies Cancer Treat Rev 34 Suppl 1 S31 S42 1:CAS:528:DC%2BD1cXmvVOnsrg%3D 10.1016/j.ctrv.2008.03.005 18486346
7. RC Coombes LS Kilburn CF Snowdon R Paridaens on behalf of the Intergroup Exemestane Study, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 1:CAS:528:DC%2BD2sXhvVGgsro%3D 10.1016/S0140-6736(07)60200-1 17307102
8. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group JF Forbes J Cuzick A Buzdar A Howell JS Tobias M Baum 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07)70385-6 18083636
9. RE Coleman LM Banks SI Girgis LS Kilburn, et al. 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119 127 1:CAS:528:DC%2BD2sXhtlSgt7c%3D 10.1016/S1470-2045(07)70003-7 17267326
10. R Eastell JE Adams RE Coleman A Howell, et al. 2008 Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 J Clin Oncol 26 1051 1057 1:CAS:528: DC%2BD1cXktVKisbo%3D 10.1200/JCO.2007.11.0726 18309940
11. RE Coleman on behalf of the ATAC Trialists' Group 2008 Long-term effects of anastrozole on bone mineral density: seven-year results from the ATAC trial J Clin Oncol 26 15S Abstract 587
12. EA Perez RG Josse KI Pritchard JI Ingle S Martino B Findlay, et al. 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635 1:CAS:528:DC%2BD28XovVSjsLc%3D 10.1200/JCO.2005.05.4882 16822845
13. DM Reid J Doughty R Eastell SD Heys, et al. 2008 Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group Cancer Treat Rev 34 Suppl 1 S3 S18 1:CAS:528:DC%2BD1cXmvVOnsrs%3D 10.1016/j.ctrv.2008.03.007 18515009
14. P Hadji J-J Body MS Aapro A Brufsky, et al. 2008 Practical guidance for the management of aromatase inhibitor-associated bone loss Ann Oncol 19 1407 1416 1:STN:280:DC%2BD1cvotVOrsA%3D%3D 10.1093/annonc/mdn164 18448451
15. Sl Hines HK Jorn KM Thompson JM Larson 2010 Breast cancer survivors and vitamin D: a review Nutrition 26 255 262 1:CAS:528:DC%2BC3cXhs1OiurY%3D 10.1016/j.nut.2009.08.020 20004077